Byron Lam, AGTC (F), Allergan, Inc. (F), Allergan, Inc. (C), Biogen, Inc. (F), Biogen, Inc. (C), Editas (F), ProQR (F), Spark Therapeutics, Inc. (F);
Robert MacLaren, Biogen, Inc. (C), Biogen, Inc. (F), University of Oxford (P);
M. Fischer, Adelphi Values (C), Advent France Biotechnology (C), AlphaSights (C), Arctos (C), Atheneum (C), Axiom Healthcare Strategies (C), Biogen, Inc. (F), Biogen, Inc. (C), Decision Resources (C), Dialectica (C), Frontera Therapeutics (C), Janssen Research & Development (C), Navigant/Novartis (C), RegenxBio (C), Roche (C), Sirion (F), Sirion (C), STZevetrial (F), STZevetrial (C);
Frank Holz, Acucela (F), Acucela (C), Acucela (R), Allergan (F), Allergan (R), Apellis (C), Apellis (R), Bayer (C), Bayer (F), Bayer (R), NightStarX (F), Novartis (F), Novartis (C), Novartis (R), Roche/Genentech (C), Roche/Genentech (F), Roche/Genentech (R);
Mark Pennesi, Adverum (C), AGTC (C), Allergan/Editas (C), Astellas Pharmaceuticals (C), Atsena (S), Biogen, Inc. (C), Blue Rock (C), DTx (S), Endogena (S), Eyevensys (S), Gensight (S), Horama (S), IVERIC (C), Nacuity Pharmaceuticals (S), Nayan (S), Novartis (C), Ocugen (S), Ora (C), ProQR Therapeutics (S), RegenexBio (C), Roche (C), Sparing Vision (S), Vedere (S), Viewpoint Therapeutics (C);
David Birch, AGTC (C), AGTC (F), Biogen, Inc. (F), Editas (C), Iveric (C), Nacuity (C), ProQR (C), ProQR (F), Roche-4D (C), Roche-4D (F);
Eeva-Marja Sankila, Bayer (C), Bayer (R), Biogen, Inc. (C), Blueprint Genetics (C), Novartis (C), Novartis (R);
Isabelleanne Meunier, None;
Kimberly Stepien, AGTC (F), Atsena Therapeutics (S), Biogen, Inc. (F), FFB (F), Opsis Therapeutics (S), Spotlight Therapeutics (C);
Juliana Sallum, Acucela (F), Biogen, Inc. (C), FFB (F), Janssen (C), Novartis (C), ProQR (F);
Cindy Lu, Biogen, Inc. (E);
Jiajun Liu, Biogen, Inc. (E);
Dan Yoon, Biogen, Inc. (E)